LianBio (LIANY)

Market Cap	7.57M
Revenue (ttm)	n/a
Net Income (ttm)	-87.98M
Shares Out	108.17M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	0.38 (542.86%)
Ex-Dividend Date	Jul 15, 2025

Volume	100
Average Volume	52,910
Open	0.0756
Previous Close	0.0700
Day's Range	0.0756 - 0.0756
52-Week Range	0.0300 - 0.4394
Beta	0.41
RSI	59.15
Earnings Date	Aug 13, 2025

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 163
• Stock Exchange: OTCMKTS
• Ticker Symbol: LIANY